reason report
where growth look similar growth re-rat
depend nash
bottom line gilead top- bottom-lin beat sequenti
revenu growth encourag next year guidanc
suggest fundament improv enough alter outlook
stock long-anticip return revenu growth
disappoint given loss exclus loe
letairi ranexa revenu shift neg
gross-to-net trend look anoth defens year
neither materi revenu growth eros unfortun
flat top line associ signific increas
oper expens support continu commerci hiv
hcv prepar launch nonalcohol steatohepat nash
rheumatoid arthriti ra compani futur much depend
continu perform hiv portfolio perform
mid-to-l stage pivot trial jak inhibitor filgotinib array
medicin develop nash phase readout
selonsertib sickest patient advanc degre
fibrosi biggest test gilead nash portfolio riski
trial initi base small phase ii studi patient
trial readout immin limit evid
endors own stock ahead catalyst quarter
increas near-term revenu estim reflect
slower eros legaci hiv product howev reduc
pro forma ep estim reflect higher expens base
chang peer compani multipl increas price target
reiter market perform rate
revenu due hiv out-performance without
one-tim inventori build total revenu
consensu estim howev gilead
announc revenu due season inventori
purchas favor payer mix mean organ revenu
beat consensu also impli similar inventori draw
like total hiv/hbv product sale street
expect estim upsid came
legaci product truvada atripla stribild remain
seen whether appar persist legaci brand
durabl hiv/hbv sale grew sequenti boost
on-going strong biktarvi launch continu growth truvada prep
segment season inventori payer mix impact hiv
gener european countri start intensifi
declin persist total hcv sale
averag price-to-earnings large-cap revenu
multipl slower-growth medic co
sum part exist franchis
net debt total capit
year price history/av daili volume mil
compani inform svb leerink llc research
revenu mm non-gaap ep ex stock option expens
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
consensu estim reflect
declin patient treat gilead hcv medicin sale non-
antivir product primarili boost letairi expect
declin due presum gener introduct quarter howev
manag disclos launch expect reflect
guidanc result suffer two increment channel
inventori declin increas chang payer mix
eros hcv product effect report real growth
challeng guidanc suggest least absenc
signific new product approv revenu
ep miss due higher expens one-tim item
gilead product gross margin includ
write-off inventori reserv harvoni without item
gross margin would consensu
expect non-gaap consensu
forecast non-gaap sg
consensu estim gs higher
due season stock grant reflect run-rat
oper margin declin percentag point due one-
time season item without harvoni write oper
margin would rang would still
consensu
estim effect tax rate
consensu also reflect run-rat due
item non-gaap ep miss consensu
estim
guidanc flat revenu poor expens manag
divers portfolio gilead issu guidanc first time
conjunct earn releas manag expect
product sale recent consensu
estim prior estim
guidanc inclus hcv sale
non-hcv product sale similar last year also anticip
sequenti product sale headwind due
donut hole inventori drawdown payer mix expens gilead
announc product gross margin line
recent consensu estim prior estim gilead
also expect non-gaap
recent consensu line prior updat
estim sg expens expect
materi recent consensu
prior line updat estim final
manag expect effect tax rate line
recent consensu estim updat estim
rate gilead stock market perform price target gilead matur
gener biotech compani search next wave innov growth
compani leader hiv medicin busi increas alreadi domin market
share indic expect hiv product sale grow peak
expect signific eros legaci tdf franchis gilead
also built lead posit hepat medicin busi continu show
sign steadi declin headi peak net two downgrad stock
sept chang hcv market forecast compani fallen
total revenu hcv sale declin stabil
compani experi moder revenu eros two franchis believ
worth compani recent share price rest compani pipelin
consist mainli kinas inhibitor filgotinib recent acquir program
yescarta time least question timelin valu
near term compani outlook much depend result pivot trial
nash medicin immedi selonsertib trial disappoint compani
stock price could suffer multipl compress expect compani revenu remain
rang next year earn hover rang
level stock seem like enjoy multipl line ex-growth matur
hiv busi trend encourag us dismal eu tale two franchis gilead
us hiv busi grew eu hiv busi declin us busi
continu benefit launch biktarvi best hiv launch date
annual importantli biktarvi also earn market share patient
switch dolutegravir lead hiv product gsk gilead main competit
past year number patient truvada pre-exposur prophylaxi prep
grown patient one-third us hiv-infect patient popul
gilead medicin trend market share gain prep expans like continu
opposit hiv sale eu declin gilead unsur growth return
downward pressur result multipl medicin lose share recent gener
launch failur gilead taf-bas product launch equal success us
trajectori exampl biktarvi achiev us sale eu
sale dynam increas gilead geograph revenu mix hiv
increas estim heavi relianc
us revenu period bipartisan support drug price reform potenti risk gilead
stock though hiv medicin remain protect class us compani reli
price increas hiv revenu growth manag unlik forecast forc price
eros guidanc long-term plan
hcv market stabil quarterli revenu eros guid
gilead treat global hcv patient flat look ahead gilead
guid hcv sale base forecast sale eros
result equat quarterli run-rat declin
next four quarter mark eas lost
hiv revenu ride descovi prep phase data gilead us
patient truvada pre-exposur prophylaxi prep total us hiv-
infect patient gilead medicin prep grown meaning pillar
compani hiv revenu patent truvada expir us gilead
attempt switch patient descovi phase trial compar descovi truvada
prep on-going data expect studi peopl
enrol two key question whether descovi effect whether
safeti advantag truvada translat prep popul although safeti
advantag descovi like applic hiv-infect individu
chronic care gilead maintain durat therapi prep longer
anticip compel argument switch popul base
estim roughli gilead total hiv revenu conting upon thesi play
revenu could risk either trial fail show safeti benefit descovi unlik
view healthcar provid manag prep indic close hiv-
infect indic requir patient use gener truvada possibl view
biggest pipelin event selonsertib nash studi separ monotherapi
phase studi selonsertib inhibitor fulli enrol fibrosi
patient read respect two program contain
patient trial increas respons rate placebo gilead
plan file simultan two studi close
togeth one posit one neg gilead would need bring data fda
defend abil file success popul current model
selonsertib simpli use revenu multipl sale discount back
wacc estim everi expect sale stock move
urgenc filgotinib regulatori file understood manag last year gilead
report first success phase trial filgotinib rheumatoid arthriti gilead
report final two studi methotrexate-inadequ respond
biologic-inadequ respond expect two trial small confirmatori event
gilead potenti upsid secur best-in-class potenti label regard safeti
howev file filgotinib still gate behind phase ii manta safeti studi men
ulcer coliti current show estim primari complet date januari
call gilead announc fda recent allow expans inclus criteria
enhanc enrol clinic trial list also show multipl studi site
open europ asia cast broader net patient recruit chief rival jak
molecul mp upadacitinib expect approv gilead keenli awar
late-mov disadvantag face filgotinib especi consid
compani rel inexperi market autoimmun drug
small svb leerink revenu earn estim increas base result
quarter manag commentari increas revenu estim
forecast gilead total revenu flat begin grow
one year reduc total hcv revenu forecast
increas estim longer term captur plateau
busi appear increasingli like report manag guidanc
also increas total hiv revenu forecast next three year larg
driven longev legaci product truvada genvoya revenu estim
consensu long term ebit margin forecast
percentag point lower year reflect higher commerci spend guidanc
lower gross margin tax rate estim rel stabl share count estim
decreas result pro forma ep estim reduc
ep estim recent consensu
base chang revenu forecast ep estim cash flow
increas price target gilead maintain market perform
rate gilead stock
price target inc base averag four approach
believ reason basi valu stock today approach trough
price earn multipl larg cap slow-growth medic product busi long term
revenu multipl larg cap biopharma product stock slow growth outlook sum
part valuat exist franchis discount cash flow dcf use trough consensu
forward earn multipl slow-growth medic product stock celg
appli ep estim gilead give price
altern appli ex-growth large-cap medic product
azn gsk nv revenu multipl revenu estim deriv
impli valu impli one year price target use sum part valuat
exist franchis get price consist primarili price
compani hiv franchis lastli dcf use forecast free cash flow
appli growth rate termin cash flow forecast discount valu back
present wacc give present valu averag four
approach price target
risk view outlook valuat gilead includ major chang label
price reimburs coverag compani exist hiv hcv product emerg
aggress price discount rebat valu eros hiv hcv
categori current forecast failur compani princip pipelin
asset selonsertib nash filgotinib ra ibd advanc develop
commerci opportun better perform valu expect includ
delay limit develop profil adopt competit hiv product
success develop underappreci element compani portfolio
selonsertib inhibitor fxr agonist inhibitor follow-on car-
indic stronger-than-expect convers current hiv patient gilead next
royalti contract revenu
non-gaap cost good sold
share count period basic
guidanc
dilut ep impact relat acqusit
stock-bas compens
svb leerink llc research compani file zack factset consensu
svb leerink llc research compani file zack factset consensu
late stage pipelin program includ
late stage pipelin program exclud
million
symtuza darunavir/c/f-taf royalti
symtuza darunavir/c/f-taf royalti
svb leerink llc research compani file
million
sale incl emori amort
 total revenu
sg total revenu
profit share total revenu
svb leerink llc research compani file
brand
type event
event trial detail
date known
up/down
leerink view
file fda regulatori approv mcl
phase ii testicular safeti filgotinib result
manta gate nda
svb leerink llc research compani file
analysi stock price svb leerink target
method trough price earn multipl larg cap slow growth biopharma compani
trough larg cap valu healthcar stock multipl ep celg
impli valuat ep
number period
equiti
method revenu multipl slow growth outlook larg cap biopharma stock appli
svb leerink revenu estim gilead
comp ex growth larg cap revenu multipl
impli valu gilead revenu
share outstand gilead
impli year price base revenu
method part valuat exist franchis kite
method dcf base current late stage pipelin product declin flow
wacc growth termin period
present valu late stage market product flow termin valu
net debt
present valu late stage market product flow
averag method
svb leerink llc partner research compani file factset
